Mirati Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mirati Therapeutics, Inc.
Mpox And Newfound ‘Punching Power’ Are Bringing Bavarian Nordic Closer To $1bn Target
Bavarian Nordic managed to change its financial story in 2022 when its smallpox vaccine, Jynneos, became a critical tool in the global response to the mpox pandemic. CEO Paul Chaplin speaks to In Vivo about what this year holds in store.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Stock Watch: Funding Biotech In A Hostile Environment
When the traditional fundraising window closes and clinical, regulatory or commercial success eludes, other routes to raise cash emerge. But these have also become more scarce recently, leaving all-stock consolidations.
Global Top 10 Medtechs Swap Places After Latest Quarterlies
Abbott Laboratories moved above Medtronic in MAT medtech revenues, while Philips Healthcare and Stryker finished 2022 with strong quarters, and Roche dropped a few places.
- Other Names / Subsidiaries
- MethylGene Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.